Your browser doesn't support javascript.
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
Shen, Xiaoying; Tang, Haili; Pajon, Rolando; Smith, Gale; Glenn, Gregory M; Shi, Wei; Korber, Bette; Montefiori, David C.
  • Shen X; Duke University, Durham, NC sxshen@duke.edu.
  • Tang H; Duke University, Durham, NC sxshen@duke.edu.
  • Pajon R; Moderna, Cambridge, MA.
  • Smith G; Novavax, Gaithersburg, MD.
  • Glenn GM; Novavax, Gaithersburg, MD.
  • Shi W; National Institute of Allergy and Infectious Diseases, Bethesda, MD.
  • Korber B; Los Alamos National Laboratory, Los Alamos, NM.
  • Montefiori DC; Duke University, Durham, NC david.montefiori@duke.edu.
N Engl J Med ; 384(24): 2352-2354, 2021 06 17.
Article in English | MEDLINE | ID: covidwho-1171035
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: N Engl J Med Year: 2021 Document Type: Article Affiliation country: NEJMc2103740

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: N Engl J Med Year: 2021 Document Type: Article Affiliation country: NEJMc2103740